We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Specific Media for Varied Modalities to Drive Growth in the European Contrast Media Markets

By MedImaging staff writers
Posted on 09 Aug 2007
In spite of challenges such as reimbursement policies, pricing, saturation, and high levels of competition, the European contrast media markets are experiencing steady growth. Product innovation, together with the introduction of novel, application-specific contrast media, is boosting market expansion.

Frost & Sullivan (Palo alto, CA, USA), an international growth consultancy company, found that the European Contrast Media Markets earned revenues of US$1.37 billion in 2006 and estimates this to reach $2.23 billion in 2013.

"Newer contrast media being developed for specific applications are displaying improved results and supporting consistent market growth,” said Frost & Sullivan research analyst Ranjit Ravindranathan. "The rising number of procedures that require contrast media is directly contributing to an increase in the number of modality installations and promoting market expansion.”

The European contrast media markets are demonstrating considerable potential, with all segments at varied stages of the growth curve. For instance, saturation in the X-ray/computed tomography (CT) field is being offset by strong growth in the magnetic resonance imaging (MRI) segment due to its enhanced applications, including in cardiology.

However, saturation in certain segments such as X-ray contrast is hindering overall market growth. Another challenge is to widen customer bases by developing innovative, application-specific products.

"Due to market maturity, the lack of, or low reimbursement rates, have an even greater effect,” added Mr. Ravindranathan. "Rising procedural costs, including the purchase of new technology with specific contrasts might prove to be a constraint initially, however, in the long-term, transition and adoption will be inevitable.”

To penetrate local markets, participants should acquire or establish strategic alliances with smaller firms, according to Frost & Sullivan. Companies should also introduce innovative products to encourage regular purchases by end users. Furthermore, market participants should train and educate radiologists about the availability and effectiveness of new contrast media technologies using radioactive contrasts.


Related Links:
Frost & Sullivan
40/80-Slice CT System
uCT 528
Silver Member
X-Ray QA Device
Accu-Gold+ Touch Pro
X-Ray Illuminator
X-Ray Viewbox Illuminators
Diagnostic Ultrasound System
DC-80A

Channels

Nuclear Medicine

view channel
Image: This artistic representation illustrates how the drug candidate NECT-224 works in the human body (Photo courtesy of HZDR/A. Gruetzner)

Radiopharmaceutical Molecule Marker to Improve Choice of Bladder Cancer Therapies

Targeted cancer therapies only work when tumor cells express the specific molecular structures they are designed to attack. In urothelial carcinoma, a common form of bladder cancer, the cell surface protein... Read more

Imaging IT

view channel
Image: The new Medical Imaging Suite makes healthcare imaging data more accessible, interoperable and useful (Photo courtesy of Google Cloud)

New Google Cloud Medical Imaging Suite Makes Imaging Healthcare Data More Accessible

Medical imaging is a critical tool used to diagnose patients, and there are billions of medical images scanned globally each year. Imaging data accounts for about 90% of all healthcare data1 and, until... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.